New start-ups join the PSCC BOOST program
Five new innovative oncology projects have been selected through the PSCC selection process and are joining the Paris-Saclay Cancer Cluster (PSCC) BOOST program, alongside more than 80 projects already supported.
From AI-powered proteomics and liquid biopsy to novel therapeutic approaches, innovative preclinical models and immunotherapy, these projects once again illustrate the diversity of innovations supported by the PSCC to accelerate their development for the benefit of patients.
Newly selected projects
BeLiver – A 2026 i-Lab Award winner, BeLiver is developing an AI-powered proteomics platform to select the most effective therapy for each liver cancer patient.
CLEOMICS – Develops AI-powered liquid biopsy tests based on extrachromosomal circular DNA (eccDNA) to enable early cancer detection and treatment monitoring.
Oncoshift – A 2026 i-Lab Award winner, Oncoshift is developing first-in-class molecules targeting metabolic adaptation to promote a durable anti-cancer response.
Owl Lifesciences – Develops a human immunocompetent neurovascular mini-brain platform combining vascularized brain tissue models with AI-driven analysis to improve CNS drug discovery and predict treatment efficacy before clinical trials.
Tidewave Bio – Develops a universal, off-the-shelf cancer immunotherapy platform for solid tumors, combining gene-modified allogeneic antigen-presenting cells with a patient's own tumor biopsy.
Comprehensive support
The PSCC BOOST program currently supports more than 80 innovative oncology projects. It provides them with access to a comprehensive range of resources and expertise to accelerate their development, including scientific expertise, networking, funding, data and samples, technologies, infrastructure, training and laboratory facilities.
Are you developing an innovation in oncology?
Discover the BOOST program and apply to benefit from PSCC support.
Are you developing an innovative solution for cancer patients? Find out how to apply to the BOOST program:
